BDR Pharmaceuticals launches Favipiravir under brand name 'BDFAVI' at Rs 63 per tablet in India

BDR pharma has received an approval from the DCGI to manufacture Favipiravir to treat mild to moderate patients with COVID-19 symptoms. The drug has been launched under the brand name 'BDFAVI'.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2EUb6Vx
via IFTTT